carcinoembryonic antigen (cea)

Carcinoembryonic antigen peptide 1 (CEA peptide) is a Carcinoembryonic Antigen (CEA) derived peptide, of which sequen is YLSGANLNL. CEA is a broad-spectrum tumour marker, a glycoprotein produced by colorectal cancer tissues, which acts as an antigen to elicit an immune response.

Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer.

Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC).

Cergutuzumab (RG7813) is a tumor-targeted immunocytokine comprising a humanized anti-CEA monoclonal antibody fused to an engineered interleukin-2 variant (IL-2v). By specifically binding to Carcinoembryonic Antigen (CEA) on tumor cells, Cergutuzumab delivers IL-2v directly to the tumor microenvironment. This selectively activates cytotoxic CD8+ T cells and NK cells while minimizing the systemic toxicity typically associated with wild-type IL-2 therapy.

hT84.66-M5A is a humanized IgG1 antibody targeting carcinoembryonic antigen (CEA). For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Arcitumab is a murine monoclonal antibody Fab fragment that targets carcinoembryonic antigen (CEA). It can be labeled with technetium-99m, enabling its use in single-photon emission computed tomography (SPECT) imaging.